Treatment of T-cell prolymphocytic leukemia with human CD52 antibody

Journal of Clinical Oncology

Volumn 15, Issue 7, 1997, Pages 2667-2672

  Pawson, R ^a   Dyer, M J S ^a   Barge, R ^a   Matutes, E ^a   Thornton, P D ^a   Emmett, E ^a   Kluin Nelemans, J C ^a   Fibbe, W E ^a   Willemze, R ^a   Catovsky, D ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; PENTOSTATIN;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE MARROW APLASIA; BRAIN TOXICITY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; INAPPROPRIATE VASOPRESSIN SECRETION; MALE; PRIORITY JOURNAL; PROLYMPHOCYTIC LEUKEMIA; T CELL LEUKEMIA; TREATMENT OUTCOME;

EID: 0030812012     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.7.2667     Document Type: Article

References (17)

1. Matutes E, Brito-Babapulle V, Swansbury J, et al: Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 78:3269-3274, 1991
2. Mercieca J, Matutes E, Dearden C, et al: The role of pentostatin in the treatment of T-cell malignancies: Analysis of response rate in 145 patients according to disease subtype. J Clin Oncol 12:2588-2593, 1994
3. Dillman RO, Shawler DL, Dillman JB, et al. Therapy of chronic lymphocytic leukemia and cutaneous T-cell lymphoma with T101 monoclonal antibody. J Clin Oncol 2:881-891, 1984
4. Knox S, Hoppe RT, Maloney D, et al: Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 87:893-899, 1996
5. Reichman L, Clark M, Waldmann H, et al: Reshaping human antibodies for therapy. Nature 332:323-327, 1988
6. Hale G, Xia M-Q, Tighe HP, et al: The CAMPATH-1 antigen (CDw52). Tissue Antigens 35:118-127, 1990
7. Isaacs JD, Watts RA, Hazleman BL, et al: Humanised monoclonal antibody therapy for rheumatoid arthritis. Lancet 340:748-752, 1992
8. Hale G, Waldmann H: Control of graft-versus-host disease and graft rejection by T-cell depletion of donor and recipient with CAMPATH-1 antibodies. Results of matched sibling transplantation for malignant disease. Bone Marrow Transpl 13:597-611, 1994
9. Hale G, Dyer MJS, Clark MR, et al: Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody, CAMPATH-1H. Lancet 2:1394-1399, 1988
10. Dyer MJS, Hale G, Hayhoe FGJ, et al: Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: Influence of antibody isotype. Blood 73:1431-1439, 1989
11. Dyer MJS, Hale G, Marcus R, et al: Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1H monoclonal antibodies. Leukemia Lymphoma 2:179-193, 1990
12. Bowen AL, Zomas A, Emmett E, et al: Subcutaneous CAMPATH-1H in fludarabine-resistant chronic lymphocytic and B-prolymphocytic leukaemia. Br J Haematol 96:617-619, 1997
13. Osterborg A, Fassas AS, Anagnostopoulos A, et al: Humanised CD52 monoclonal antibody CAMPATH-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 93:151-153, 1996
14. Nethersell ABW, Fussell JC, Daly DJ, et al: Interim clinical results of phase I/early phase 2 CAMPATH-1H studies in NHL/CLL. Fifth International Conference on Malignant Lymphoma. Lugano, Switzerland, April 1993, p 107 (abstr)
15. Hale G, Clark M, Waldmann H: Therapeutic potential of rat monoclonal antibodies: Isotype specificity of antibody-dependent cell-mediated cytotoxicity with human lymphocytes. J Immunol 134:3056-3061, 1985
16. Gilleece MH, Dexter TM: Effect of CAMPATH-1H antibody on human hemopoietic progenitors in vitro. Blood 82:807-812, 1993
17. Dyer MJS, Kelsey SM, Mackay HJ, et al: In vivo "purging of residual disease in CLL with CAMPATH-1H. Br J Haematol 1997 (in press)